Impact of antiresorptive agents on mortality risk in postmenopausal women with osteoporosis: insights from a nationwide cohort study
Kyoung Jin Kim,Seong Hee Ahn,So Young Park,Jimi Choi,Gi Hwan Bae,Ha-Young Kim,Kyoung Min Kim,KSBMR Epidemiology Study Group,Tae-Young Kim,Jung Wee Park,Committee Members,Hae Sun Suh,Hoejeong Chung,Jae-Hwi Nho,Jun-Il Yoo,Miso Jang,Seunghyun Lee,Young-Kyun Lee
DOI: https://doi.org/10.1093/ejendo/lvae111
2024-08-30
Abstract:Importance: Osteoporosis-related fractures are associated with increased mortality risk among postmenopausal women, yet the impact of antiosteoporotic medications on mortality is not fully understood. Objective: This study evaluates the effect of antiresorptive agents (ARs) on mortality risk in postmenopausal women with osteoporosis. Design: This is a nationwide cohort study using data from the National Screening Program for Transitional Ages (2008-2017). Setting: Data were derived from a national cohort of postmenopausal women in South Korea. Participants: This study included 117 871 postmenopausal women diagnosed with osteoporosis. Of them, 15 895 patients who used ARs, such as bisphosphonates or selective estrogen receptor modulators, for at least 1 year were matched 1:1 with nonusers using propensity scores. Exposures: Exposure to ARs for at least 1 year was compared with no AR use. Main outcomes and measure: Mortality outcomes were assessed using multivariable Cox proportional hazard regression models, focusing on all-cause mortality and cause-specific mortality, particularly cardiovascular disease (CVD) and injury-/fracture-related deaths. Results: In AR users, there were 102 deaths (mortality rate 1.41 per 1000 person-years), compared with 221 deaths in non-users (mortality rate 3.14 per 1000 person-years), yielding a hazard ratio (HR) of 0.43 (95% CI, 0.34-0.54). Antiresorptive agent users showed a 52% reduction in CVD mortality risk (HR, 0.48; 95% CI, 0.34-0.69) and a 54% reduction in injury-/fracture-related mortality risk (HR, 0.46; 95% CI, 0.27-0.76). The analysis indicated a consistent decrease in all-cause and CVD mortality risks with longer durations of AR use. Conclusions and relevance: The use of ARs in postmenopausal women with osteoporosis is associated with significantly lower risks of all-cause mortality, especially from cardiovascular events and fractures. The mortality reduction benefits appear to be enhanced with prolonged AR therapy, highlighting the potential importance of sustained treatment in this population.